InChord acquires U.K. based advertising agency

Share this article:
InChord Communications, the largest privately-held healthcare communications company in the world, has acquired Junction 11, a U.K.-based healthcare advertising agency.
Terms of the deal were not reported.
The acquisition will enable inChord to expand its European capability by combining Junction 11's staff and client base with its existing GSW Worldwide operation in London. GSW Worldwide is inChord's flagship advertising agency. 
The new agency will be known as GSW Worldwide/Junction 11 and will be led by Stephen Wheatley, who recently joined GSW Worldwide as president of the agency's UK operations. Wheatley most recently served as chief executive at Euro RSCG Life.  He previously held positions with TBWA, Foote Cone and Belding, Euro RSCG Group and Ogilvy and Mather Advertising. 
GSW Worldwide/Junction 11 will be based in London and will maintain an office in Surrey, England, through early 2005. Clients include Eli Lilly, GlaxoSmithKline, Roche, Johnson & Johnson and Shire.
GSW Worldwide/Junction 11 will serve as the European hub for GSW Worldwide's global network, which includes affiliate agencies in 13 countries across the globe.
The new agency will employ approximately 25 people.  Senior leadership will include Richard Rayment and John Timney, formerly of Junction 11, who will serve as co-creative directors; and Richard Hart, formerly of Junction 11, who will serve as client services director.
Junction 11 founder John Greenwood will help manage the agency transition over the next several weeks, with a planned retirement at the end of the year.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.